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Preface
An Expert Meeting on The Current Scientific and
Legal Status of Alternative Methods to the LD50
Test for Botulinum Neurotoxin (BoNT) Potency
Testing was organised by the Centre for
Documentation and Evaluation of Alternatives to
Animal Experiments (ZEBET) at the Federal
Institute for Risk Assessment (BfR), and took
place on 27–28 April 2009, in Berlin, Germany.
The goal of ZEBET is to promote primarily the
replacement of legally required animal experiments with valid alternative test methods, to
reduce the numbers of test animals used to the
absolutely necessary level, and to alleviate their
pain and suffering. ZEBET’s tasks are the documentation, assessment and promotion of alternative methods to animal experiments on a national
and international level, and the initiation of
research and development, including the funding
of smaller research projects.

The Expert Meeting on alternative methods for
Botulinum neurotoxin (BoNT) potency testing was
held at the BfR as the result of a decree from the
German Federal Ministry of Food, Agriculture and
Consumer Protection (BMELV), after it was
informed by German state authorities about an
increase in animal numbers being used in the
LD50 potency test in mice for the purposes of
BoNT potency testing. Ethical concerns have been
raised in both Europe and the United States about
the animal suffering involved in this type of testing, especially in the context of BoNT’s aesthetic
applications. There had been increased public
pressure on the German Government, due to successful campaigning by animal welfare/anti-vivisectionist organisations on the issue of BoNT
animal testing. As a result, the BMELV asked
ZEBET to assess the status of the different alternative methods to the BoNT LD50 potency test
that are cited in the European Pharmacopoeia
(EP) 6.0, Monograph 2113, Botulinum Toxin Type
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A for Injection (1), and the most promising
approaches for their validation. Experts from
industry, regulatory authorities, German ministries, academia, research, national and international validation centres, and animal welfare
organisations, were invited to actively participate
in the meeting.
The objective of the Expert Meeting was to
review available alternative methods for BoNT
potency testing, and to formulate recommendations for making progress toward implementing
the Three Rs, i.e. Refinement, Reduction, and
Replacement, in BoNT potency testing. In addition,
ways in which communication on BoNT issues
between manufacturers, researchers and regulators could be encouraged, and how improvements
in regulatory harmonisation between different
countries and continents could be achieved, were
discussed. The meeting started with presentations
by the individual participants, giving an overview
on the regulatory and scientific status of alternative methods to the LD50 test for BoNT potency
testing. Afterwards, the participants were divided
into two separate break-out groups. Break-out
Group 1 discussed the regulatory requirements for
BoNT potency testing and the validation and
implementation of alternative methods. Break-out
Group 2 discussed the developed and available
alternative methods and their suitability for reducing, refining or replacing the LD50 potency test.

Introduction
Botulinum neurotoxin is a biological product produced by the anaerobic, Gram-positive bacterium
Clostridium botulinum. There are seven major and
serologically distinct serotypes (A–G) of BoNT,
characterised by a complex mode of action, which
results in blockage of acetylcholine release at
neuro-muscular nerve endings, leading to flaccid
paralysis. This mechanism of toxicity comprises
the four stages of binding, internalisation, translocation and proteolytic cleavage of a substrate,
which leads to inhibition of synaptic exocytotoxic
transmitter release. The different serotypes of
BoNT act on different substrates.
BoNT-A and BoNT-B are available as licensed
pharmaceuticals for the treatment of a variety of
medical disorders, such as cervical dystonia, blepharospasm, spastic conditions and hyperhidrosis.
However, BoNT is also used in so-called ‘aesthetic
medicine’ to temporarily treat facial asymmetries
or reduce facial lines. BoNT is of biological origin,
and has an extremely high toxic pharmacological
activity. Therefore, the safe and effective dosing of
BoNT products requires accurate and reliable
measurement of potency before batch release onto
the market. The reference test for potency testing
in the batch release of therapeutic BoNT, as well
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as for the detection of the toxin in clinical cases of
botulism, is the mouse bioassay. In diagnostic testing, the serotype needs to be identified and the
amount of toxin quantified. The detection of
Clostridium botulinum in clinical samples, with
subsequent identification and typing of the toxic
culture supernatant by mouse bioassay, is often
included in routine testing. This permits the identification of toxico-infections and delivers isolates
for further testing and toxin-typing, either in further animal experiments, or by molecular methods.
In the manufacture of pharmaceutical BoNT
products, the serotype and subtype of the toxin are
well defined. The focus is on the biological activity
of BoNT, which needs to be determined as accurately as possible, for the purposes of both safety
and efficacy, to ensure that the correct potency of
the product is supplied to clinicians for patient
treatment. The current requirements of the EP for
potency determination are based on standard practice, as approved in the marketing authorisations
of products for the EU market, which stipulates
that every production lot of BoNT must be tested
in an LD50 potency test in mice. For a valid assay,
the dilution range used should encompass the
LD50 value. In practice, this can mean that at the
highest dose, 90% of the animals are killed, and at
the lowest dosage, 90% of the animals survive.
Importantly, the precision of the test depends on
dilution intervals and the number of animals used
per concentration. The product dosage for patients
is determined by the outcome of the potency assay.
In the case of BoNT LD50 potency testing, the
dosing of animals is associated with severe suffering. Death is generally secondary to respiratory
failure due to paralysis of the respiratory muscles.
Consequently, the introduction of alternative
methods is urgently required. A number of alternative tests have been developed in the past few
decades, to replace the mouse bioassay. Additionally, promising methods are under development, which may, either alone or in combination
with other assays, meet the rigid requirements of
potency testing. To encourage movement away
from the LD50 test, the possibility of using a validated in-house alternative to the LD50 assay has
been included in the EP monograph (1).

The Toxic Mechanism of BoNT
BoNT induces muscle paralysis by blocking the
release of acetylcholine at neuro-muscular nerve
endings (2). BoNTs are composed of a 100kDa
heavy chain and a 50kDa light chain (3, 4). The
heavy chain is responsible for binding to a receptor
located on the membrane of the neuron and
translocation of the light chain, whereas the light
chain acts as a highly specific proteolytic enzyme
once internalised into the cell. BoNTs act via a
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complex mechanism (5) that comprises binding to
cell surface, high affinity receptors of cholinergic
nerve endings (6, 7), penetration into the plasma
membrane by endocytosis (8), and pH-dependent
translocation of the light chain from the lumen of
the vesicles into the cytoplasm. The light chain
acts as a zinc-dependent protease that cleaves one
or more components of a membrane fusion complex
composed of syntaxin, SNAP-25 (a synaptosomalassociated protein) and synaptobrevin, thereby
blocking exocytosis (9, 10). As a result of this cleavage event, the release of acetylcholine at the neuromuscular junction is inhibited, leading to a
subsequent flaccid muscular paralysis.

Previous Meetings on BoNT Potency
Testing
Two previous meetings were held in 2006, with the
goal of promoting alternative methods to the LD50
potency test. These were: a meeting hosted by the
European Directorate for the Quality of Medicines
and Health Care (EDQM) of the Council of Europe;
and a workshop in the USA organised by the US
Interagency Coordinating Committee on the
Validation of Alternative Methods (ICCVAM), the
US National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM) and the
European Centre for the Validation of Alternative
Methods (ECVAM), in response to a nomination by
the Humane Society of the United States (HSUS).
The outcomes of these two meetings were reported
and discussed at the ZEBET meeting in Berlin.

The EDQM Meeting
Catherine Milne, from the EDQM, reported on the
Botulinum Toxin 3R Strategy Meeting, hosted in
April 2006 by the EDQM, in Strasbourg, France.
The participants included representatives of the
three manufacturers of BoNT-A marketed in
Europe, representatives from EU official national
testing laboratories and licensing authorities,
ECVAM and the EDQM. In addition, a conference
call with authorities from the US Food and Drug
Administration (FDA) Center for Drug Evaluation
and Research (CDER), Health Canada, and ICCVAM was included, in order to permit the exchange
of views in a more global context. The goal of the
meeting was to look to the future for potency testing
of BoNT in the context of the application of the
Three Rs principles, supported by the relevant conventions of the Council of Europe and EU Directives.
The consensus was that the LD50 assay would
remain the ‘gold standard’ for validation of alternative methods, but that this can only be used in a
product-specific and method-specific setting due to
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method variability between laboratories, lack of
common reference standards for the LD50 assay,
and the need to maintain product-specific unitage.
This should be taken into account as the alternative methods are being developed and validated.
It was agreed that in any replacement strategy,
all the functions of the toxin (cell binding, internalisation, translocation and endopeptidase activity) would have to be assessed. This could be via a
single assay or by a multi-assay approach.
A reduction strategy, involving a full assay
approach for the bulk toxin (covering all three
functions) and a simplified approach for the final
product lot release, measuring a reduced set of criteria to monitor consistency, was considered to be
worth investigating, as all lots would be derived
from the same bulk toxin. Examples of this type of
approach are already allowed in the EP, and are in
use for human vaccines. The usefulness of this
approach would be tightly linked to the definition
of the robustness and reproducibility of the actual
production process and the GMP controls in place.
The potential problems that might arise in the
clinic if the unitage was changed, were a significant concern. The expression of units for alternative assays could be expressed in LD50 equivalents
to avoid problems in the clinic. Possibilities for this
would need to be further explored.
Based on the data presented, the product-specific aspects of the LD50 assay and the complications related to unitage, no clear candidate for a
common method or reference was identified at that
time. Nevertheless, the participants were open to
the idea of exchanging reagents and data with the
authorities, in order to facilitate development
work, and the EDQM expressed a willingness to
organise collaborative studies on the alternative
methods in the context of the biological standardisation programme, once they had been further
explored and established.

The ICCVAM/NICEATM/ECVAM
Workshop
Martin Stephens, from the HSUS, reported on the
ICCVAM/NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce and
Replace the Mouse LD50 Assay for Botulinum
Toxin Testing, that was held in Silver Spring, MD,
USA, in November 2006. About 115 participants,
mostly from Europe and North America, participated in this workshop, including scientists from
governmental and academic institutions, national
and international regulatory authorities, industry,
and the animal welfare community.
The consensus of the panel discussions at the
ICCVAM/NICEATM/ECVAM Workshop (http://
iccvam.niehs.nih.gov/methods/biologics/bot_
workshop.htm) was that some of the alternative
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methods could be used in specific circumstances, or
in a tiered-testing strategy, to reduce and refine
the current LD50 assay. However, none of the
methods reviewed could be used individually as a
complete replacement for the mouse potency assay
at that time. The panel discussions noted that,
with additional development and validation
efforts, one or more of the reviewed methods might
be useful as a replacement for some of the current
BoNT testing applications in the future. Finally,
some best practices were discussed for decreasing
the numbers of animals used, including the establishment of reference standards, the employment
of standardised methodology, and reduction in the
number of doses tested for assays when confirmation of potency is being evaluated.
It was reported at the 2009 Expert Meeting in
Berlin that the US workshop in 2006 succeeded in
bringing together international experts who work
on disparate applications of the LD50 assay and
alternatives for BoNT testing, and provided a
snapshot of the status quo. It was less successful in
fulfilling its stated goal of developing a set of
strategic recommendations for future actions.

The Regulatory Framework
Regulation on the protection of animals
used for scientific purposes, according to
Directive 86/609/EEC
The protection of animals used for experimental
and other scientific purposes is regulated in
Europe by Directive 86/609/EEC, which is currently under revision (11). Among the aims of the
directive is the reduction of the numbers of animals used for experiments, by requiring that an
animal experiment should not be performed when
an alternative method exists, and by encouraging
the development and validation of alternative
methods to replace animal methods. Furthermore,
it requires the minimisation of any pain, suffering
and distress caused to test animals. The Member
States of the European Union have implemented
the Directive 86/609/EEC into their legislations.
However, some of the member states, including
Germany and the UK, have implemented national
animal welfare acts that go beyond the requirements stated in Directive 86/609/EEC.

Regulations for the marketing of
pharmaceutical products
European regulations
In Europe, the LD50 testing of BoNT, i.e. the bulk
drug substance and the final drug product lot, is a
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requirement of the EP Monograph 2113, Botulinum Toxin Type A for Injection (1). EP monographs and texts are the legally binding quality
standards for all medicinal products in the EU.
The individual marketing authorisations for products marketed in the EU must apply these standards according to the EU Directive for Human
Medicines 2001/83/EC (12), as amended by
Directive 2004/27/EC (13).
The method currently used for the potency testing of all BoNT-A pharmaceutical products on the
EU market, as accepted in the marketing authorisations by the European regulatory authorities, is
the LD50 assay. Nevertheless, the specific monograph and the general notice open the possibility of
developing alternative methods, in particular in
the interest of animal welfare and the Three Rs.
Since 2005, three different alternative approaches
have been noted in the EP Monograph 2113,
Botulinum Toxin Type A for Injection (1), but users
are not limited to these methods, which are: “an
endopeptidase assay in vitro, an ex vivo assay
using the mouse phrenic nerve diaphragm, and a
mouse bioassay using paralysis as the endpoint.”
Furthermore, it is stated in the EP that alternative
methods must be suitably validated in comparison
to the reference method, which is the LD50 assay:
“After validation with respect to the LD50 assay
(reference method), the product may also be assayed
by other methods that are preferable in terms of
animal welfare, including one of the above mentioned.”
EP Monograph 2113, Botulinum Toxin Type A
for Injection (1), is currently under consideration
for revision. The revision provides additional
details for a refined in vivo assay as an alternative
to the LD50 potency assay that uses local paralysis
as an endpoint. Moreover, a new monograph for
BoNT type B for injection is under development,
which presents a similar strategy for potency testing as for BoNT type A. The new and revised monographs were published in July 2009 in
Pharmeuropa 21.3, for public consultation (14, 15).

FDA regulations
In the USA, FDA regulates BoNT products as
drugs. The FDA requires the submission of data on
BoNT potency, as well as on safety, purity, sterility and other parameters for these products. The
regulations are specified in the Code of Federal
Regulations 21 Chapter I (16). Although the FDA
requires the appropriate potency testing of BoNT
products, and specifies the performance attributes
of such a test, it does not state which particular
test should be used. While recognising that the
international standard is the mouse LD50 potency
assay, the FDA will also review data submitted in
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support of alternative potency assays and, when
warranted, issue formal approval for their use.

Quality Guidelines (ICH and EMA)
The LD50 potency test is not only performed for
release testing of BoNT, but also for other manufacturing purposes (Figure 1). For the marketing
authorisation application, stability testing of drug
substance and drug product is required. In addition,
according to the principles of Good Manufacturing
Practice (GMP), annual stability studies have to be
performed after the medicinal products have been
authorised. International (Europe, USA and Japan)
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) Guideline Q5C, Stability Testing
of Biotechnological/ Biological Products, requires,
for products that are linked to a definable and measurable biological activity, that testing for potency
should be part of the stability studies (17).
Furthermore, for the marketing authorisation
application process in Europe, validation studies
are required by the regulatory authorities of the
Member States that demonstrate the suitability
and reproducibility of the manufacturing process.
The development of new formulations or products
also requires additional process validation and
stability studies, where LD50 tests are performed
(ICH Q5E; 18).

Validation Requirements for
Alternative BoNT Potency Assays
The basis for successful validation studies for
alternative bioassays is ICH guideline Q2
Validation of Analytical Procedures (19). Since the
LD50 tests of the different BoNT-producing companies vary and are product-specific (20, 21), the
specific alternative methods have to be validated
for each individual medicinal product. In this context, no standard validation programme can be
applied, but individual validation plans have to be
developed.
For the successful validation of an alternative
assay, the specificity, reproducibility, precision,
range and robustness have to be demonstrated.
During the development and validation of the
alternative method, sources of variability should
be identified and variability should be minimised.
The number of batches required for a successful
validation and cross-validation with the LD50 test,
and acceptable statistical limits, are key discussion points for validation requirements.
The Federal Institute for Drugs and Medical
Devices (BfArM), and other European Regulatory
Agencies, each offer the opportunity for companies
to discuss their development plans and strategies
at an early stage. These early discussions between
manufacturers and regulatory authorities can be
beneficial in facilitating the process of regulatory
acceptance of alternative methods, and can help

Figure 1: A schematic overview of the BoNT production process, demonstrating when
potency tests are required to meet regulatory requirements
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product
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Potency test (ICH Q5C)
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Potency tests are required in the EP for the bulk purified toxin and final reconstituted product. In addition, potency
tests have to be performed according to the ICH, to demonstrate the product stability over time (ICH Q5C) and for
process validation (ICH Q5E).
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manufacturers to plan appropriate validation
studies on methods, such that they ultimately
meet the regulatory requirements.
In this context, the question arose at the ZEBET
Expert Meeting, of whether a general guidance
document on the validation of alternative methods
to the BoNT LD50 potency test would be helpful.
However, the experts agreed that validation of
such methods could not be generalised, since guidance for product-specific validation can only be
given by the regulatory authorities in close communication with the manufacturers before and
during the validation process, and will be specific
for the particular product, the proposed alternative
potency testing method used, and the data set generated.
Workshop participants from the regulatory
authorities stated at the meeting that after the
successful product-specific validation of a suitable
alternative method and regulatory acceptance of a
specific product, it would be easier for later applicants to achieve regulatory acceptance of the same
method for use with other products. However, comprehensive data will need to be provided by each
applicant. The experts also agreed that, from a
pharmaceutical point of view, there would be no
obvious reason why a method that could replace
the LD50 potency test for one specific product
should not work for the other products, as the
BoNT-A medicinal products currently on the market do not differ in their modes of action.

Alternative Methods in Product
Stability and Process Validation
There was discussion of whether alternative methods, unacceptable for product release alone (since
they do not cover all functions of the toxin — e.g.
the endopeptidase assay), could nonetheless be
employed for other purposes, such as the monitoring of product stability or process validation. The
participants had different opinions on this, but
agreed that, in principle, it would be desirable to
use the same assay for all testing requirements,
i.e. stability, process validation and product
release, in order to provide comparable data.
Nevertheless, this issue was also discussed with
regulatory experts. They stated that a reduced stability programme could be performed that could
employ alternative assays, e.g. the endopeptidase
assay, as a replacement for the LD50 potency
assay for at least every second control test per
year. Intermediate stability control tests would
still have to be performed with the LD50 assay, or
an alternative test reflecting fully functional activity of the toxin.
Such an approach might be acceptable in
Europe, if sufficient data were available to provide
information on the stability of the products.
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However, it was mentioned that the lack of global
harmonisation among regulatory authorities could
be a problem.

An International Reference Standard
Due to the current lack of standardisation, the
introduction of an international reference standard was discussed, to facilitate better comparison
of different products and standardised unitage.
The EP requires the use of in-house reference standards, as a common standard is currently unavailable. This is partly because of the differences
observed with the LD50 assays used for the different products, which create difficulties in establishing such a standard. There have also been concerns
over the problems that could arise in the clinic, if
the existing unitage for dosing were changed for
the individual products due to the use of a new reference unit. Nevertheless, it was argued that such
a standard could help to promote the acceptance of
alternative methods to the LD50 assay.
However, the majority of the participants suggested that the development of an international
reference standard would be time-consuming and
currently not necessary, since, for the acceptance
of alternative potency assays, product-specific validations are required that would use the in-house
standard. It was argued that the work on an international reference standard would currently delay
validation efforts.
In contrast to the development of an international standard for the harmonisation of BoNT
units, the experts recommended the development
of BoNT reference materials that would be essential for comparing alternative potency assays and
their performance in different laboratories.
Reference materials already available at the
National Institute for Biological Standards and
Control (NIBSC) could be considered for interim
use in planned method comparison studies (21).

Harmonisation
A main concern expressed at the meeting was the
lack of global consensus between regulatory
authorities on the implementation of alternative
methods for BoNT potency testing. In Europe, the
implementation of an alternative test method
requires a variation application either at the
national or at the European level. Moreover, the
world-wide implementation of alternative methods
for medicinal products is much more complex, and
is considered to be an obstacle for globally-acting
manufacturers. Some of the experts expressed
their wish to promote international harmonisation
and mutual acceptance criteria for the validation
of alternative methods.
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Establishment of a ‘BoNT Expert
Working Group’
In order to overcome current difficulties in the
development, optimisation, validation and regulatory acceptance of alternative methods to the
BoNT potency test, the experts discussed the
establishment of a ‘BoNT Expert Working Group’.
This group would deal with the essentials for
acceptability, comparability and implementation
of the Three Rs in BoNT potency testing. There
was a common agreement to initially focus on the
situation in Europe, as this could speed up the
process of the implementation of alternative BoNT
potency assays in this region.
A core group should be established, comprising
experts from European regulatory authorities,
Three Rs and validation institutions, manufacturers and scientists. Experts from overseas should be
invited as observers. In addition, a network of
additional experts and stakeholders should be
established, who would join the ‘BoNT Expert
Working Group’ on a case-by-case basis. The Group
should meet regularly up to three times per year
during a proposed time-frame of four years, and
should publish its recommendations on a regular
basis.
The objectives of the ‘BoNT Expert Working
Group’ would include, among others, providing
advice and guidance on validation requirements
for the proposed alternative methods, and defining
minimum standards for a validation framework in
order to implement the Three Rs in BoNT potency
testing. The Group would assess replacement,
refinement and reduction strategies, and review
data, reference materials, methods and scientific
approaches, and would promote the standardisation of protocols. The Group would also provide
more transparency between the stakeholders and
regulatory authorities.
All the attending participants expressed the
wish that an independent institution should be
responsible for the establishment and management of the ‘BoNT Expert Working Group’, and the
BfR/ZEBET and BfArM agreed to accept this task.

Alternative Methods to the LD50
Potency Test
Refinement assays
There are a number of opportunities for refinement of the LD50 potency assay in the potency
testing of BoNT. These could include, for example,
the use of lower species, shortening of the duration
of the procedure, and endpoints earlier than death,
which would imply an increased frequency of animal inspections and intervention when death is
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impending, as has often been the practice with
other lethal dose tests. In addition, refinement can
be achieved by alternative experimental designs
and analyses. To date, a number of these opportunities have been identified and exploited.

Humane endpoints
In the interests of the Three Rs, the conventional
LD50 test was deleted from the OECD Test
Guidelines Programme for the testing of chemicals
in 2001. It was replaced by three alternative methods, one of which includes the use of non-lethal
humane endpoints (22). This deletion was only possible after weighing the risks and benefits, thus
ensuring that all three alternative methods could
serve the regulatory needs.
For BoNT, while complete deletion of the test is
not yet possible, careful evaluation of the clinical
signs that indicate imminent death has resulted in
some success in implementing earlier (more
humane) endpoints. Such signs include cyanosis,
indrawn scaphoid abdomen, gasping, and behavioural responses such as immobility and social isolation. The application of such humane endpoints
could be undertaken without affecting the results
of the LD50 test, and data were presented that
showed that up to 21% of the animals could be successfully culled by a humane method, rather than
being allowed to die (Table 1). However, due to the
fact that it is not yet feasible to establish such endpoints at a sufficiently early time-point (Figure 2),
the current employment of humane endpoints does
not permit a significant decrease in the suffering of
the animals used.
In addition, the above-mentioned clinical signs
that should indicate imminent death have not yet
been sufficiently investigated. A change from the
lethal endpoint to the refined humane endpoints
would also require a product-specific validation

Table 1: The results of experimental studies
that applied humane endpoints
Study number

% Humane endpoint

1
2
3
4
5
6

16%
11%
11%
15%
15%
21%

Average

15%

% Humane endpoint specifies the percentage of mice
that could have been culled by a humane method rather
than going on to die, without affecting the results of the
LD50 test.
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Figure 2: The numbers of dead mice over time, following BoNT injection
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The graph shows the mean results of six independent runs.

study, and most experts recommend that further
effort should not be invested in the development of
refined assays based on humane endpoints at present, but that the focus should be on other refinement or replacement assays.

Local paralysis assays
Changing the LD50 potency assay to an alternative, less severe, test by using non-lethal endpoints, is complicated. Such alternative tests
include the mouse flaccid paralysis assay (23), the
rat muscle force (RMF) assay (24), the digital
abduction score (DAS) assay (25, 26), and the rat
gastrocnemius assay. From a Three Rs point of
view, these assays would be preferred to the LD50
potency test, as only sub-lethal doses of the toxin
are injected and animals generally fully recover
from the treatment, even at the highest dose used.
In the flaccid paralysis assay, different sublethal concentrations of BoNT are injected subcutaneously into the top of the left hind leg, the
inguinocrural region of the lower abdomen of a
mouse. The animals are then scored by two or more
observers according to the size of the local abdom-

inal bulge (Figure 3) at 24 and 48 hours, by using
a five-point scale (Table 2). This scoring system
was introduced because the method had been previously criticised for its subjective and non-quantitative read-out.
The dose–response, suitable for calculation of
potency, is obtained by plotting the scores against
the log toxin dose for the test and reference samples. Then the relative potency is calculated by a
parallel line method. This approach has been used
at the NIBSC, primarily to confirm activity in
product-specific reference preparations. At the
NIBSC, the LD50 test has not been performed for
more than 10 years (27).
The advantages of the flaccid paralysis assay are
not only a refined endpoint, but also ease of use,
fast one-off read-out (48 hours), and increased sensitivity with comparable precision, coupled with
the use of only 20% of the number of animals used
in a comparable LD50 test. Furthermore, the dosing is considered more relevant to clinical use, as
muscle paralysis rather than systemic toxicity is
evaluated. Recent potency data presented by the
NIBSC confirmed an excellent agreement with
LD50-determined potency for seven different therapeutic products.
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Figure 3: The mouse flaccid paralysis assay

The mouse on the left has been injected with BoNT to assay the potency of a test sample, and shows an abdominal
bulge at the site of injection (stage 3, Table 2), compared with the uninjected control mouse on the right (stage 0,
Table 2) (illustrations provided by D. Sesardic et al. [29]).

However, criticism was expressed by some experts
during the meeting. One of the concerns was that,
although local paralysis was a relevant endpoint, the
scoring could still be too subjective. Furthermore, it
was mentioned that the low precision of 20% —
which was the rate achieved with an 80% reduction
in animal number — may necessitate an increase in
the number of test animals used, so that the number
of animals necessary may eventually be close to that
for the LD50 test. The performance of a validation
study involving several laboratories, to confirm the
precision of the test that is referred to in the EP, was
considered to be a useful proposal.
The experts also discussed the rat muscle force
(RMF) assay, the digital abduction score (DAS)

assay and the rat gastrocnemius assay. All three
methods were evaluated as being not yet suitable
for BoNT potency testing, and the RMF assay and
the rat gastrocnemius assay were recommended
only for research purposes.
Replacement assays
Ex vivo assays
1. The mouse hemidiaphragm assay (HDA): The
HDA (28) operates with an isolated nerve muscle
preparation (Figure 4). When BoNT is added to
the organ bath in which the muscle has been

Table 2: An example of a recommended scoring scheme that is used to define the response
of individual mice in the flaccid paralysis test
Stage

Description

0

No signs, normal

1

Just detectable bulge, e.g. covering an area of approximately 0.5cm in diameter, or less.

2

More pronounced bulge, e.g. covering an area greater than 0.5cm in diameter, but less than the
maximum radius of the hind leg heel.

3

More extensive bulge extending over a larger area. Extending below hips and top of thigh when viewed
from the side and beyond the maximum radius.

4

Maximal local effect. More extensive bulge extending over a larger area. Will often extend as far as the
bottom of the rib cage, or over a large area with extensive distension or bulging.
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placed, the contraction amplitude of the nervestimulated muscle gradually declines until it disappears. The contraction of the diaphragm is
recorded isometrically, by using a force transducer, and the contraction amplitude is assessed
over time. The time at which the muscle is paral-
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ysed by 50% of the original contraction amplitude
is determined, following the application of different concentrations of BoNT. The recorded time of
the onset of 50% paralysis (t1/2) decreases with
increasing concentrations of BoNT.
The advantages of the HDA are fast read-out (a

Figure 4: The hemidiaphragm assay

The hemidiaphragm assay operates with an isolated nerve muscle preparation that is placed in an organ bath. The
contraction of the diaphragm is recorded isometrically, by using a force transducer, and the contraction amplitude is
assessed over time (illustrations provided by H. Bigalke).
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few hours) and full functionality. This is an organotypic assay — which means that the animals are
humanely killed, and the determination of BoNT
potency is then carried out on the isolated nerve
muscle preparation. The method is technically
challenging and requires sophisticated and expensive equipment. The robustness of the assay was
tested at the Medical School of Hannover, in the
presence of human serum with various protein and
lipid concentrations. The test was validated for
measurement of the presence of antibodies to neurotoxin in sera from BoNT-treated patients, and
was shown to fulfil the criteria of specificity, selectivity and precision for this purpose. A validation
study for BoNT potency testing by using the HDA
began in 2009, in collaboration with Merz
Pharmaceuticals.
The discussions at the Expert Meeting revealed
a number of questions that could not be answered
at present, e.g. the product specificity of the
assay, the strain specificity of the ex vivo material, and the comparability of the steepness of the
concentration–response curves of the HDA and
the LD50 assay. Recent published data from the
NIBSC identified improved precision with an
inbred mouse strain, but also observed supplierspecific differences in A toxin activity in the HDA
(29).
2. The intercostal neuromuscular junction (NMJ)
assay: Another ex vivo assay discussed at the
Expert Meeting was the intercostal NMJ assay,
which uses ex vivo rat intercostal muscle preparations (30). As described above for the HDA, this ex
vivo assay still requires the killing of animals
(rats), but successfully addresses the question of
their suffering. Up to six individual rat intercostal
rib sections can be obtained from a single rib cage.
Upon treatment with BoNT injected directly into
the tissue sections, the contractile response is
monitored upon electrostimulation of the intercostal nerve over time. The NMJ assay was evaluated by the experts as an assay that employs a
relevant endpoint and reduces the suffering of the
animals used. However, a pre-validation study
with this assay, performed by one manufacturer,
was unsuccessful. The experts at the meeting considered that this might have been due to the relatively small size of the muscle preparations. The
tissue size employed in the HDA, for example, is
substantially bigger, and the phrenic nerve is a relatively robust nerve.

In vitro assays
1. Cellular assays: Potency assays based on cells
offer an advantage over other in vitro models, as
they provide information on all the essential steps
in the BoNT intoxication process, i.e. binding,
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internalisation and intracellular activity. In theory, only the cell-based assays have the potential
to fully replace animal-based potency tests for all
applications. Furthermore, they could be applied
to all stages of the production process, including
the testing of the purified bulk active toxin component.
Despite active research in this field, no suitable
assays with the desired sensitivity and characteristics for the potency assessment of toxin-based
products are yet available. Primary neuronal cells,
derived from rat spinal cords, have been extensively studied and confirmed to offer the desired
sensitivity. However, robustness and reproducibility have been limiting factors so far in the introduction of such methods within a quality control
setting. Human cell lines of neuronal lineages
would provide the best option in the testing of
BoNT potency, but, up to now, none of the available cell lines have offered the required sensitivity,
unless they were fully differentiated to neuronal
cell types.
A number of cell-based assays for potency testing are currently under development by experts
from both the NIBSC and Allergan, Inc. Strategies
at the NIBSC have focused on the differentiated
human neuroblastoma cell line, SH-SY5Y. With
these cells, the inhibition of depolarisation-evoked
neurotransmitter release is measured after incubation with botulinum toxin. In addition, collaborative studies with the NIBSC Scientific Division
of Cell Biology and Imaging (CBI), have provided
the opportunity to study differentiated cell lines
and human stem cells that were grown in multielectrode dishes. With such dishes, the spontaneous electrical activity of the cells can be recorded
before and after BoNT exposure. Although these
approaches showed increased sensitivity to picomolar levels of BoNT, it was anticipated at the
meeting that they are not sufficiently robust for
quality control testing, but are likely to remain
useful research tools.
Another strategy focused on by the NIBSC, was
the development of a new generation cell-based
endopeptidase assay that employs antibody reagents
already used in the SNAP-25 ELISA format. In addition, new antibodies were generated for the capture
and detection of SNAP-25, and an optimum protocol
for the sensitive capture of recombinant SNAP-25
and cleaved SNAP-25 from cell lysates was developed. The sensitivity of the method was confirmed in
the fully-differentiated human neuronal cell line,
SH-SY5Y, although primary rat spinal cord cells
offered greater sensitivity in Western blotting (31)
and immunodetection of cleared SNAP-25 (unpublished data). However, robustness and precision in
comparison to the conventional LD50 assay have not
yet been assessed, so further studies are necessary.
Allergan Inc. have developed a novel cell-based
screening Western blot assay for measuring BoNT
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activity, based on a SNAP25197-specific antibody.
They have reported substantial progress in the
optimisation of the assay, resulting in increased
sensitivity and improvements in assay read-out.
Another ongoing project, involving collaboration
between the University of Veterinary Medicine
Hannover and the Georg-August University of
Göttingen, focuses on the development of a BoNT
testing assay based on the human teratocarcinoma
cell line, Ntera2 (NT-2). These cells can be differentiated into fully functional, post-mitotic neurons,
which display a variety of neurotransmitter phenotypes (Figure 5; 32). In this project, the process
to generate post-mitotic neurons was significantly
shortened to approximately four weeks’ duration
(33). During differentiation, the NT-2 acquired
typical neuronal markers, such as beta-tubulin
type III, MAP-2 and phosphorylated tau, and grew
neural processes which expressed punctate
immunoreactivity for synapsin and synaptotagmin, suggesting the formation of synaptic structures. A major subset of the model neurons showed
immunoreactivity to the cholinergic markers,
choline acetyltransferase and vesicular acetylcholine transporter. Moreover, spontaneous postsynaptic currents in glia-free cell cultures were
detected, which result from the firing of excitatory

and inhibitory NT-2 neurons (34). These spontaneously-active neural networks may be a useful
tool in the detection of BoNT potency in blocking
neurotransmission, by using cell physiological
techniques.
The experts have extensively reviewed the use of
cell-based assays, in order to determine acceptable
cell types for the BoNT potency assays. They
agreed that primary neuronal cells are not
favoured from a regulatory point of view, as they
are too variable. No primary cells are currently
being used by industry to develop new BoNT
assays. Cell lines, on the other hand, are easier to
standardise than primary neuronal cells, but often
are not as sensitive when used in assays. If used in
BoNT potency assays, cell lines must first be very
well characterised.
In addition, the experts discussed the cell types
that would be best suited for testing the potency of
BoNT. They expressed different opinions about the
suitability of neuronal cells, either alone or in combination with muscle cells. Some experts thought
that cells applied in a potency assay should resemble, as closely as possible, motor neurons.
However, other experts believed that any cells that
could reflect the action of BoNT, from receptor
binding, to SNAP-25 cleavage or blocking of trans-

Figure 5: The in vitro differentiation of NT-2 cells into post-mitotic neurons

a)

b)

100μm

50μm

a) Expansion of NT-2 cells in free floating cell spheres. This technique resembles the sphere culture method used in
embryonic stem cell differentiation. b) Post-mitotic NT-2 neurons, showing the immunofluorescent staining of a
neuronal marker. Spindle shaped cell bodies send out processes that form a neural network (illustrations provided by
G. Bicker, H. Böhnel and F. Gessler).
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mitter release, would be useful. In addition, the
importance of the species of origin of the cells was
discussed. The question arose as to whether neuromuscular junctions should be cholinergic in a
BoNT potency test, or could be also glutaminergic,
as, for example, found in some lower species. Some
experts thought it would be fundamental for a test
to be based on a system with cholinergic neuromuscular junctions. However, others thought that
the transmitters would not be of importance, but
solely the substrate, SNAP-25, as BoNT would also
act on different types of glands.
There are a number of challenges associated
with the use of cellular BoNT potency assays. The
experts agreed that a key problem with the cellbased assays currently under investigation, was
the relatively flat dose–response curves seen, in
comparison with the LD50 assay. This observation
was explained by the minimum signal resulting
from a cell due to the low amount of transmitters
released. This effect is amplified in vivo or in
organotypic assays, due to the muscle activity,
especially in the voltage-dependent channels.
A steep concentration–response curve was considered necessary, as a good separation of the
tested concentrations is of great importance. The
EP monograph requires a potency specification
between 80% and 125% (1). Therefore, three to five
concentrations have to be tested in this range.
The experts discussed how the cell signals could
be amplified in vitro. They agreed that transgenic
cell lines, e.g. Green Fluorescent Protein (GFP)expressing cell lines or cells over-expressing receptors or substrate, could result in steeper
concentration–response curves and therefore provide suitable in vitro models for BoNT potency
testing. In addition, the incubation time of BoNT
in the potential assay will have an influence on the
steepness of the concentration–response curve.
Finally, it was emphasised by the experts that
cells are the minimum accepted unit that can cover
all the steps of the BoNT mechanism of toxicity. To
go beyond this level to molecular assays would
require a combination of different test methods.
However, no cell-based assays are as yet at a stage
appropriate for a validation study.

Molecular assays

Endopeptidase assays
The information on the intracellular mode of
action of BoNTs provided the opportunity to
develop enzyme cleavage assays. A series of papers
were published, in which endopeptidase assays
were applied to BoNT drug products (35–37). The
approach has been validated in-house at the
NIBSC for a particular product, and has been in
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use for the last five years, to confirm the manufacturer’s claim of potency against a product-specific
reference preparation. The NIBSC reported that,
by using the endopeptidase assay, it was possible
to detect nanogramme quantities of toxin in the
presence of high concentrations of bulking agents
and stabilisers in the final product, with superior
sensitivity and excellent agreement with the
mouse LD50. Furthermore, the assay afforded a
high precision that was superior to that of the in
vivo models and, in addition, ease of use, robustness and ready transferability. The NIBSC has
recently improved the assay protocol (38), and now
considers this to be an excellent method for the
evaluation of trends and consistency.
The method has been criticised for its inability to
reflect all the functional domains of the toxin
known to contribute to the in vivo activity, as only
the light chain activity is measured. The experts
agreed that it could be promising in support of
potency testing for process validation and stability,
but might not be suited for product release. On the
other hand, some experts considered the endopeptidase assay to be suitable for assigning the
potency of the final product after successful product-specific validation, if the potency of the final
bulk was assessed by an assay able to cover the
whole toxic mechanism of BoNT.

Binding and translocation assays
Binding and translocation assays are available,
but are still at the research stage. Ipsen, for example, has developed a ganglioside binding assay.
The reagents for such assays are not yet commercially available and may be of limited use, in view
of the fact that gangliosides might not be high
affinity receptors for the toxins.

Combination of molecular assays
Due to the fact that molecular assays can only provide information on single steps in the toxicological
mechanism of BoNT, various tests would have to
be combined in order to provide all the necessary
information on potency. The experts discussed how
different assays could be combined, and agreed
that this would be a very difficult task, as different
tests would provide different potency values
(units) that would have to be linked or weighted in
some way.

Public Funding
The experts recommended increased funding on
research into cellular neurotoxicity mechanisms,
in order to identify relevant mechanisms for novel
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assays, and into feasibility and prevalidation studies of existing methods. Furthermore, it was
reported that funding possibilities exist from the
German Federal Ministry of Education and
Research, and that also the US National Institute
of Health is currently funding small enterprises for
the development of alternative assays for BoNT
potency testing.

Reduction of Animal Numbers and
Refinement of the LD50 Assay
Allergan and Ipsen reported a substantial reduction in the numbers of animals used in the LD50
potency test. Allergan have improved their dosing
range, which has resulted in the testing of fewer
doses and the requirement for fewer animals per
dose. By using this approach, they could reduce the
animal numbers by 50%. Ipsen stated that they
have reduced the testing time from 96 to 72 hours,
which resulted in a reduction of suffering (refinement). Merz informed the participants of the meeting that these approaches have also been in
practice at their facilities, since the beginning of
their own BoNT product development.

Conclusions and Recommendations
1. The industry and scientists have made progress
in implementing reduction and refinement in
BoNT potency testing, and in the development
of alternative potency assays.
2. General guidance on the product-specific validation of alternative methods for BoNT potency
methods cannot be provided. Guidance on product-specific validation is given continuously by
regulatory authorities to manufacturers, both
before and during the validation process.
3. Regulatory authorities should actively be
involved in international harmonisation and in
defining mutual acceptance criteria for alternative methods to LD50 potency testing.
4. A ‘BoNT Expert Working Group’ should be established, to provide advice on validation requirements for alternative methods, define minimum
standards for a validation framework, assess
refinement and reduction strategies, review data,
test methods, reference materials and scientific
approaches, and promote the standardisation of
protocols. BfR/ZEBET, in collaboration with
BfArM, will be responsible for establishing the
‘BoNT Expert Working Group’.
5. Funding should be made available and its use
coordinated, to develop and validate alternative
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methods for BoNT potency testing according to
the Three Rs principles. In particular, the
development of a replacement alternative for
BoNT testing should have the highest priority.
6. Reference materials should be developed to promote the comparability of different BoNT
potency assays.
7. Alternative methods that are not yet able to
replace the LD50 test in all steps of the production process may still be useful in testing for
product stability, process validation or lot
release.
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